Pre-clinical companies

Syncona’s pre-clinical portfolio companies are developing their pipelines, proprietary platforms and progressing towards entering clinical trials.

Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: repairing inflammatory organ damage, chronic renal diseases, melanoma, multiple myeloma, heart attacks and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.

Key facts

Unless stated all financials at 31 March 2024


Value of pre-clinical portfolio


No. of companies


Portfolio company Board seats

Our pre-clinical portfolio companies